Table 2.
Published Case Series of Craniopharyngioma Post-Op Morbidities.
| Author(s) | Year | Total Patients | GTR (n) | GTR Morbidity | STR (n) | STR Morbidity | STR+RT (n) | STR+RT Morbidity |
|---|---|---|---|---|---|---|---|---|
| Clark et al.27 | 2012 | 531 | 191a | ED 108 (59%) | 46a | ED 27 (59%) | 24a | ED 11 (46%) |
| DI 46 (25%) | DI 6 (13%) | DI 1 (4%) | ||||||
| Obesity 10 (6%) | Obesity 0 (0%) | Obesity 1 (4%) | ||||||
| PH 27 (15%) | PH 2 (4%) | PH 7 (29%) | ||||||
| VD 9 (5%) | VD 2 (4%) | VD 1 (4%) | ||||||
| ND 20 (11%) | ND 5 (11%) | ND 0 (0%) | ||||||
| Kim et al.20 | 2012 | 146 | 53 | VD 8 (15%) | 41 | VD 21 (51%) | 52 | VD 10 (19%) |
| Schoenfeld et al.6 | 2012 | 122 | 33 | DI 18 (55%) | 41 | DI 11 (27%) | 48 | DI 6 (13%) |
| PH 21 (64%) | PH 12 (29%) | PH 12 (25%) | ||||||
| VD 7 (21%) | VD 6 (15%) | VD 5 (10%) | ||||||
| Park et al.24 | 2017 | 116 | 54 | ED 26 (48.1%)VD 4 (7.8%) | 44 | ED 17 (40.5%)VD 2 (4.5%) | 18 | ED 11 (61.1%)VD 2 (11.1%) |
| Totalb | 915 | 331 | ED 134 (55% ± 5.8%) | 172 | ED 44 (48.9% ± 9.1%) | 142 | ED 22 (52.4% ± 7.7%) | |
| DI 64 (29% ± 18.6%) | DI 17 (19.5% ± 7%) | DI 7 (9.7% ± 4.6%) | ||||||
| Obesity 10 (6% ± 0%) | Obesity 0 (0%± 0%) | Obesity 1 (4% ± 0%) | ||||||
| PH 49 (22% ± 30.1%) | PH 14 (16.1% ± 12.5%) | PH 19 (26.4% ± 2%) | ||||||
| VD 28 (8.5% ± 7.3%) | VD 31 (18% ± 19.2%) | VD 18 (12.7% ± 5.6%) | ||||||
| ND 20 (11% ± 0%) | ND 5 (11% ± 0%) | ND 0 (0% ± 0%) |
Abbreviations: DI, diabetes insipidus; ED, endocrine dysfunction; ND, neurologic dysfunction; PH, panhypopituitarism; VD, visual dysfunction.
aNumbers reflect patients with follow-up.
bTotal percentages were calculated based on the total number of patients in whom the morbidity was evaluated.